Puma Biotechnology (PBYI) 57.48 $PBYI
Puma (PBYI) Neratinib's Application Validated in EU, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:37AM CDT
Puma (PBYI) announced that its Marketing Authorization Application for neratinib has been validated by the European Medicines Agency.
ANIP: 59.86 (-1.56), PBYI: 57.48 (-1.23)
Research Report Initiation on Biotech Stocks -- PTC Therapeutics, Grifols, Puma Biotech, and 22nd Century
PR Newswire - Mon Aug 22, 6:50AM CDT
Stock-Callers.com today has issued research reports on PTC Therapeutics Inc. (NASDAQ: PTCT), Grifols S.A. (NASDAQ: GRFS), Puma Biotechnology Inc. (NYSE: PBYI), and 22nd Century Group Inc. (NYSE MKT: XXII). These stocks belong in the Biotech arena, which over the recent weeks has slowly started to bounce back. In the past three months, the NASDAQ Biotech Index has risen 12%, while the S&P 500 has gained 6.9%. Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
XXII: 1.05 (+0.02), PTCT: 7.91 (+0.12), GRFS: 16.04 (+0.14), PBYI: 57.48 (-1.23)
The Zacks Analyst Blog Highlights: Apple, Exact Sciences, Amkor Technology, Puma Biotechnology and Chemours
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 8:30AM CDT
The Zacks Analyst Blog Highlights: Apple, Exact Sciences, Amkor Technology, Puma Biotechnology and Chemours
AMKR: 9.25 (+0.01), CC: 13.63 (+0.16), EXAS: 18.64 (+0.45), AAPL: 107.73 (+1.00), PBYI: 57.48 (-1.23)
4 Biggest Winners from This Earnings Season
Swarup Gupta - Zacks Investment Research - Thu Aug 18, 1:39PM CDT
Though both earnings and revenues continue to decline year-over-year, results have improved from the preceding quarter.
AMKR: 9.25 (+0.01), CC: 13.63 (+0.16), EXAS: 18.64 (+0.45), AAPL: 107.73 (+1.00), PBYI: 57.48 (-1.23)
Puma (PBYI) Posts Narrower Loss in Q2, Focus on Neratinib
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 9:17AM CDT
Puma Biotechnology (PBYI) reported a narrower-than-expected second-quarter 2016 loss of $2.05 per share.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), CORT: 5.31 (-0.04), PBYI: 57.48 (-1.23)
Puma Biotechnology Reports Second Quarter 2016 Financial Results
BusinessWire - Tue Aug 09, 3:33PM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2016.
PBYI: 57.48 (-1.23)
What's in the Cards for Puma (PBYI) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:51AM CDT
Puma Biotechnology (PBYI) is expected to report second-quarter 2016 results on Aug 8. The company posted a negative surprise of 17.74% last quarter.
IPXL: 24.03 (+0.09), MYL: 39.97 (-1.95), PBYI: 57.48 (-1.23)
PBYI August 5th Options Begin Trading
DividendChannel.com - Thu Jun 23, 9:43AM CDT
Investors in Puma Biotechnology, Inc. saw new options begin trading today, for the August 5th expiration.
PBYI: 57.48 (-1.23)
Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 8.12 (-0.11), JAZZ: 120.84 (-2.47), GRFS: 16.04 (+0.14), PBYI: 57.48 (-1.23)
Puma (PBYI) Presents Favorable Phase II Data on Neratinib
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:33AM CDT
Puma Biotechnology (PBYI) presented positive data from a phase II study on neratinib in patients with HER2-mutated, non-amplified breast cancer at ASCO.
ANIP: 59.86 (-1.56), AZN: 33.31 (+0.71), RTRX: 16.10 (-0.25), PBYI: 57.48 (-1.23)
Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting
BusinessWire - Sun Jun 05, 8:05AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, presented positive results from an investigator-sponsored Phase II trial of neratinib with HER2-mutated, non-amplified breast cancer. The data were presented today in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, Illinois. The poster (Abstract #516), entitled "Phase II Trial of Neratinib for HER2 Mutated, Non-Amplified Metastatic Breast Cancer (HER2mutMBC)," was presented from 8:00-11:30 a.m. CDT today with a poster presentation discussion occurring immediately following the poster session.
PBYI: 57.48 (-1.23)
Sunesis Pharmaceuticals Appoints Linda Neuman, M.D., as Vice President, Clinical Development
GlobeNewswire - Wed Jun 01, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Linda Neuman, M.D., has been appointed to the role of Vice President, Clinical Development. Dr. Neuman brings 10 years of clinical practice and 13 years of industry experience to Sunesis, most recently serving as Senior Medical Director of Oncology at Puma Biotechnology.
SNSS: 0.81 (+0.01), PBYI: 57.48 (-1.23)
Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting
BusinessWire - Wed May 18, 4:05PM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2016, in Chicago. Abstracts are available to the public online on the ASCO website: www.abstract.asco.org.
PBYI: 57.48 (-1.23)
Puma (PBYI) Reports Wider Loss in Q1, Neratinib in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:06AM CDT
Puma Biotechnology (PBYI) reported a wider-than-expected loss of $2.19 per share in the first quarter of 2016.
ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), BMY: 56.35 (-0.41), PBYI: 57.48 (-1.23)
Puma Biotech reports 1Q loss
Automated Insights - Tue May 10, 5:06PM CDT
LOS ANGELES (AP) _ Puma Biotechnology Inc. (PBYI) on Tuesday reported a loss of $71 million in its first quarter.
PBYI: 57.48 (-1.23)
Puma Biotechnology Reports First Quarter 2016 Financial Results
BusinessWire - Tue May 10, 3:17PM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2016.
PBYI: 57.48 (-1.23)
Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.43 (-0.02), INO: 9.08 (-0.06), VVUS: 1.05 (-0.01), TEVA: 51.22 (+0.32), ARNA: 1.57 (+0.01), PBYI: 57.48 (-1.23)
What Awaits Puma Biotechnology (PBYI) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:58PM CDT
Puma Biotechnology (PBYI) is expected to report first-quarter 2016 results on May 9.
IPXL: 24.03 (+0.09), JAZZ: 120.84 (-2.47), PBYI: 57.48 (-1.23)
Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference
BusinessWire - Wed May 04, 7:35AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:40 a.m. PDT on Wednesday, May 11, at the Bank of America Merrill Lynch 2016 Health Care Conference. The conference will be held at Encore at the Wynn in Las Vegas.
PBYI: 57.48 (-1.23)
Puma Biotechnology's NEfERT-T Phase II Study Published Online in JAMA Oncology
BusinessWire - Thu Apr 14, 10:10AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that results from the NEfERT-T Phase II clinical trial of neratinib in ERBB2-positive metastatic breast cancer patients were published online in JAMA Oncology. The article, entitled "Neratinib Plus Paclitaxel vs. Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial," appears in the April 14, 2016 online issue and will be published in a future print issue of the journal.
PBYI: 57.48 (-1.23)
Puma (PBYI) Neratinib's Application Validated in EU, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:37AM CDT
Puma (PBYI) announced that its Marketing Authorization Application for neratinib has been validated by the European Medicines Agency.
ANIP: 59.86 (-1.56), PBYI: 57.48 (-1.23)
Research Report Initiation on Biotech Stocks -- PTC Therapeutics, Grifols, Puma Biotech, and 22nd Century
PR Newswire - Mon Aug 22, 6:50AM CDT
Stock-Callers.com today has issued research reports on PTC Therapeutics Inc. (NASDAQ: PTCT), Grifols S.A. (NASDAQ: GRFS), Puma Biotechnology Inc. (NYSE: PBYI), and 22nd Century Group Inc. (NYSE MKT: XXII). These stocks belong in the Biotech arena, which over the recent weeks has slowly started to bounce back. In the past three months, the NASDAQ Biotech Index has risen 12%, while the S&P 500 has gained 6.9%. Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
XXII: 1.05 (+0.02), PTCT: 7.91 (+0.12), GRFS: 16.04 (+0.14), PBYI: 57.48 (-1.23)
The Zacks Analyst Blog Highlights: Apple, Exact Sciences, Amkor Technology, Puma Biotechnology and Chemours
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 8:30AM CDT
The Zacks Analyst Blog Highlights: Apple, Exact Sciences, Amkor Technology, Puma Biotechnology and Chemours
AMKR: 9.25 (+0.01), CC: 13.63 (+0.16), EXAS: 18.64 (+0.45), AAPL: 107.73 (+1.00), PBYI: 57.48 (-1.23)
4 Biggest Winners from This Earnings Season
Swarup Gupta - Zacks Investment Research - Thu Aug 18, 1:39PM CDT
Though both earnings and revenues continue to decline year-over-year, results have improved from the preceding quarter.
AMKR: 9.25 (+0.01), CC: 13.63 (+0.16), EXAS: 18.64 (+0.45), AAPL: 107.73 (+1.00), PBYI: 57.48 (-1.23)
Puma (PBYI) Posts Narrower Loss in Q2, Focus on Neratinib
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 9:17AM CDT
Puma Biotechnology (PBYI) reported a narrower-than-expected second-quarter 2016 loss of $2.05 per share.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), CORT: 5.31 (-0.04), PBYI: 57.48 (-1.23)
Puma Biotechnology Reports Second Quarter 2016 Financial Results
BusinessWire - Tue Aug 09, 3:33PM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2016.
PBYI: 57.48 (-1.23)
What's in the Cards for Puma (PBYI) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:51AM CDT
Puma Biotechnology (PBYI) is expected to report second-quarter 2016 results on Aug 8. The company posted a negative surprise of 17.74% last quarter.
IPXL: 24.03 (+0.09), MYL: 39.97 (-1.95), PBYI: 57.48 (-1.23)
PBYI August 5th Options Begin Trading
DividendChannel.com - Thu Jun 23, 9:43AM CDT
Investors in Puma Biotechnology, Inc. saw new options begin trading today, for the August 5th expiration.
PBYI: 57.48 (-1.23)
Biotechnology Equities Technical Notes -- Grifols, Achillion Pharma, Jazz Pharma, and Puma Biotechnology
PR Newswire - Wed Jun 08, 7:25AM CDT
On Tuesday, June 07, 2016, the NASDAQ Composite ended the trading session at 4,961.75, down 0.14%; the Dow Jones Industrial Average advanced 0.10% to finish at 17,938.28; and the S&P 500 closed at 2,112.13, up 0.13%. The gains were broad based as eight out of nine sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Grifols S.A. (NASDAQ: GRFS), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and Puma Biotechnology Inc. (NYSE: PBYI). Learn more about these stocks by accessing their free trade alerts at:
ACHN: 8.12 (-0.11), JAZZ: 120.84 (-2.47), GRFS: 16.04 (+0.14), PBYI: 57.48 (-1.23)
Puma (PBYI) Presents Favorable Phase II Data on Neratinib
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 8:33AM CDT
Puma Biotechnology (PBYI) presented positive data from a phase II study on neratinib in patients with HER2-mutated, non-amplified breast cancer at ASCO.
ANIP: 59.86 (-1.56), AZN: 33.31 (+0.71), RTRX: 16.10 (-0.25), PBYI: 57.48 (-1.23)
Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting
BusinessWire - Sun Jun 05, 8:05AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, presented positive results from an investigator-sponsored Phase II trial of neratinib with HER2-mutated, non-amplified breast cancer. The data were presented today in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, Illinois. The poster (Abstract #516), entitled "Phase II Trial of Neratinib for HER2 Mutated, Non-Amplified Metastatic Breast Cancer (HER2mutMBC)," was presented from 8:00-11:30 a.m. CDT today with a poster presentation discussion occurring immediately following the poster session.
PBYI: 57.48 (-1.23)
Sunesis Pharmaceuticals Appoints Linda Neuman, M.D., as Vice President, Clinical Development
GlobeNewswire - Wed Jun 01, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that Linda Neuman, M.D., has been appointed to the role of Vice President, Clinical Development. Dr. Neuman brings 10 years of clinical practice and 13 years of industry experience to Sunesis, most recently serving as Senior Medical Director of Oncology at Puma Biotechnology.
SNSS: 0.81 (+0.01), PBYI: 57.48 (-1.23)
Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting
BusinessWire - Wed May 18, 4:05PM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2016, in Chicago. Abstracts are available to the public online on the ASCO website: www.abstract.asco.org.
PBYI: 57.48 (-1.23)
Puma (PBYI) Reports Wider Loss in Q1, Neratinib in Focus
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:06AM CDT
Puma Biotechnology (PBYI) reported a wider-than-expected loss of $2.19 per share in the first quarter of 2016.
ANIP: 59.86 (-1.56), RTRX: 16.10 (-0.25), BMY: 56.35 (-0.41), PBYI: 57.48 (-1.23)
Puma Biotech reports 1Q loss
Automated Insights - Tue May 10, 5:06PM CDT
LOS ANGELES (AP) _ Puma Biotechnology Inc. (PBYI) on Tuesday reported a loss of $71 million in its first quarter.
PBYI: 57.48 (-1.23)
Puma Biotechnology Reports First Quarter 2016 Financial Results
BusinessWire - Tue May 10, 3:17PM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2016.
PBYI: 57.48 (-1.23)
Drug Stocks Reporting Early Next Week: TEVA, ARNA & More
Arpita Dutt - Zacks Investment Research - Fri May 06, 8:43AM CDT
Drug companies like Teva (TEVA) and Arena (ARNA) will be reporting results early next week.
BDSI: 2.43 (-0.02), INO: 9.08 (-0.06), VVUS: 1.05 (-0.01), TEVA: 51.22 (+0.32), ARNA: 1.57 (+0.01), PBYI: 57.48 (-1.23)
What Awaits Puma Biotechnology (PBYI) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:58PM CDT
Puma Biotechnology (PBYI) is expected to report first-quarter 2016 results on May 9.
IPXL: 24.03 (+0.09), JAZZ: 120.84 (-2.47), PBYI: 57.48 (-1.23)
Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference
BusinessWire - Wed May 04, 7:35AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:40 a.m. PDT on Wednesday, May 11, at the Bank of America Merrill Lynch 2016 Health Care Conference. The conference will be held at Encore at the Wynn in Las Vegas.
PBYI: 57.48 (-1.23)
Puma Biotechnology's NEfERT-T Phase II Study Published Online in JAMA Oncology
BusinessWire - Thu Apr 14, 10:10AM CDT
Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that results from the NEfERT-T Phase II clinical trial of neratinib in ERBB2-positive metastatic breast cancer patients were published online in JAMA Oncology. The article, entitled "Neratinib Plus Paclitaxel vs. Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial," appears in the April 14, 2016 online issue and will be published in a future print issue of the journal.
PBYI: 57.48 (-1.23)
